We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

83 hedge funds and large institutions have $86.9M invested in Regulus Therapeutics in 2016 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,782% more call options, than puts

Call options by funds: $9.71M | Put options by funds: $337K

10% more capital invested

Capital invested by funds: $78.9M → $86.9M (+$8.08M)

0% more funds holding

Funds holding: 83 → 83 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

19% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 26

Holders
83
Holders Change
–
Holders Change %
0%
% of All Funds
2.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
21
Reduced
26
Closed
12
Calls
$9.71M
Puts
$337K
Net Calls
+$9.38M
Net Calls Change
+$5.38M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$2.21M
2
BCM
Bridgeway Capital Management
Texas
+$877K
3
Deutsche Bank
Deutsche Bank
Germany
+$875K
4
Wells Fargo
Wells Fargo
California
+$410K
5
HCM
Highbridge Capital Management
New York
+$357K

Top Sellers

Rank Fund Capital Flow
1
NI
Numeric Investors
Massachusetts
-$1.83M
2
OAM
Oxford Asset Management
United Kingdom
-$1.39M
3
Goldman Sachs
Goldman Sachs
New York
-$1.3M
4
CPIM
Columbia Partners Investment Management
Virginia
-$1.11M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$814K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$452K -$15.2K -37 -3%
T. Rowe Price Associates
27
T. Rowe Price Associates
Maryland
$378K +$30K +73 +8%
TAM
28
Tocqueville Asset Management
New York
$374K -$2.88K -7 -0.7%
Schroder Investment Management Group
29
Schroder Investment Management Group
United Kingdom
$363K – – –
TRSOTSOK
30
Teachers Retirement System of the State of Kentucky
Kentucky
$359K – – –
HCM
31
Highbridge Capital Management
New York
$343K +$357K +868 New
AC
32
Amici Capital
New York
$272K – – –
California State Teachers Retirement System (CalSTRS)
33
California State Teachers Retirement System (CalSTRS)
California
$271K +$2.88K +7 +1%
AA
34
ALPS Advisors
Colorado
$222K -$23.4K -57 -9%
CPIM
35
Columbia Partners Investment Management
Virginia
$219K -$1.11M -2,690 -83%
TA
36
Teachers Advisors
New York
$206K – – –
Charles Schwab
37
Charles Schwab
California
$204K – – –
Swiss National Bank
38
Swiss National Bank
Switzerland
$192K – – –
D.E. Shaw & Co
39
D.E. Shaw & Co
New York
$187K +$195K +474 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$174K – – –
Macquarie Group
41
Macquarie Group
Australia
$165K -$171K -416 -50%
AllianceBernstein
42
AllianceBernstein
Tennessee
$155K – – –
VEA
43
Virtus ETF Advisers
New York
$153K – – –
Millennium Management
44
Millennium Management
New York
$152K +$158K +385 New
BCM
45
Bourgeon Capital Management
Connecticut
$149K -$87.2K -212 -36%
ProShare Advisors
46
ProShare Advisors
Maryland
$123K -$23.4K -57 -16%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$120K +$2.47K +6 +2%
Brown Advisory
48
Brown Advisory
Maryland
$114K – – –
WS
49
Wedbush Securities
California
$107K -$50.2K -122 -31%
Morgan Stanley
50
Morgan Stanley
New York
$104K +$12.8K +31 +13%
1
2
3 4

RGLS Hedge Fund Activity: Q3 2016 in Review

83 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2016, worth a combined $86.9M — up 10% from $78.9M a quarter earlier.

Fund positioning in RGLS was balanced in Q3 2016: 12 funds opened new positions, 12 closed out, 21 added to existing stakes and 26 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.21M. The largest seller was Numeric Investors, cutting an estimated $1.83M.

  • 83 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $86.9M of Regulus Therapeutics stock for Q3 2016, up 10% quarter-over-quarter.
  • 12 funds opened new Regulus Therapeutics positions in Q3 2016 and 12 closed out, a net change of 0 holders.
  • The largest Regulus Therapeutics buyer in Q3 2016 was Renaissance Technologies, an estimated $2.21M added.
  • The largest Regulus Therapeutics seller in Q3 2016 was Numeric Investors, an estimated $1.83M sold.

Based on aggregated 13F filings for Q3 2016.